CDK4/6 inhibitors have changed the treatment paradigm for HR+/HER-2- advanced breast cancer, not only by extending the duration of endocrine therapy but also by delaying the time for patients to receive chemotherapy. This evidence concerns the gene CDK4 and breast cancer.